<i>Bifidobacterium bifidum</i> G9‐1 Survives in the Intestinal Environment and Influences the Gut Microbiota Despite the Presence of Antimicrobials
Probiotics can help prevent antibiotic-associated diarrhea; however, those lacking antimicrobial resistance may be ineffective during antimicrobial treatment. Here, we aimed to examine the effects of antimicrobials on the probiotic strain Bifidobacterium bifidum G9-1 (BBG9-1). Minimum inhibitory concentrations were determined in vitro by culturing B. bifidum G9-1 with antimicrobials and assessing its viability. For in vivo analysis, germ-free and specific pathogen-free mice were administered B. bifidum G9-1 along with antimicrobials. Gut microbiota composition and viable B. bifidum G9-1 abundance were determined. Bifidobacterium bifidum G9-1 was highly sensitive to antimicrobials in vitro. However, in a complex bacterial environment mimicking the gut environment, the abundance of viable B. bifidum G9-1 was significantly high despite antimicrobial exposure. Dominant bacterial populations were more affected by antimicrobials than nondominant populations, with B. bifidum G9-1 exhibiting increased viability in the presence of diverse bacterial species. In vivo, combined administration of antimicrobials and B. bifidum G9-1 significantly reduced B. bifidum G9-1 abundance in germ-free mice but not in specific pathogen-free mice, where the gut microbiota composition shifted following administration of B. bifidum G9-1. The presence of diverse live bacteria in the intestine promotes the survival of B. bifidum G9-1 and its beneficial effects, even in the presence of antimicrobials. This finding suggests that B. bifidum G9-1, despite lacking intrinsic antimicrobial resistance, can survive and reach the large intestine, maintaining its probiotic function. Therefore, B. bifidum G9-1 can potentially be used for antibiotic-associated diarrhea prevention.
Authors
- Yutaka Makizaki (ORCID: https://orcid.org/0000-0001-7971-7503)
- Haruka Yokota
- Hiroshi Ohno (ORCID: https://orcid.org/0000-0001-8776-9661)
- Yoshiki Tanaka (ORCID: https://orcid.org/0000-0003-0050-587X)
Publication Details
- Journal
- Microbiology and Immunology
- Published
- 2025-06-29
- DOI
- https://doi.org/10.1111/1348-0421.13230
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 0.00